Open AccessSerum Vascular Endothelial Growth Factor (VEGF) in DMPA Acceptors: Influence on Bleeding Occurrence
Author(s) -
Ratih Pratiwi,
Rizani Amran,
Usman Said,
Irsan Saleh
Publication year - 2016
Publication title -
indonesian journal of obstetrics and gynecology
Language(s) - English
Resource type - Journals
eISSN - 2338-7335
pISSN - 2338-6401
DOI - 10.32771/inajog.v3i1.22
Subject(s) - medicine , vascular endothelial growth factor , medroxyprogesterone acetate , gynecology , vaginal bleeding , vegf receptors , obstetrics , gastroenterology , pregnancy , hormone , biology , genetics
Objective: To analyze the relationship between levels of serum vascular
endothelial growth factor (VEGF) and bleeding occurrence in
depo medroxyprogesterone acetate (DMPA) acceptors.
Method: We employed a cross‐sectional study on 70 DMPA acceptors
with DMPA use of 3 to 6 months who presented for midwifery
service in Palembang. Blood samples were obtained in order
to assess levels of serum VEGF using ELISA (enzyme‐linked immunoabsorbent
assay) method. Laboratory assessments were carried
out in PRODIA laboratory in Jakarta.
Result: We recruited 70 subjects into our study. After 3 to 6 months
of using DMPA, as much as 26 subjects (37.1%) reported complaints
of bleeding and 44 subjects (62.9%) reported no bleeding. The mean
level of serum VEGF in DMPA acceptors with bleeding was 355 K
170 pg/ml, and 323 K 202 pg/ml in acceptors with no bleeding. We
identified a significant association between duration of use and
bleeding occurrence (p0.05).
Conclusion: In our sample, we found an association between duration
of DMPA use and presence of bleeding but VEGF levels was not
found to be different in women experiencing abnormal uterine
bleeding and those who did not.
Keywords: bleeding, DMPA acceptor, serum VEGF